Aplos Medical, which was formerly known as CT Resources, has reported the first successful implantation of its Omega PF device for the treatment of gastroesophageal reflux disease (GERD).

Omega PF device is said to be a first-of-its-kind device that integrates a dual-modality treatment. It facilitates the patient’s natural, unhindered swallowing process while also controlling reflux.

The procedure involving its first implantation was undertaken by Tripp Buckley at Dell Medical Center of the University of Texas at Austin.

Aplos Medical said that the implanted patient is satisfied with the results and is doing well.

Buckley said: “While Nissen fundoplication offers favourable surgical outcomes in experienced hands, the Omega device stands out for its promise of a simpler and swifter procedure, significantly reducing potential complications and side-effects.”

Aplos Medical said that any skilled surgeon can easily perform the simple laparoscopic implant procedure.

Once the clinical trials confirm the Omega PF’s efficacy, the device is expected to establish a new benchmark for care in this area.

It will also signify a paradigm shift in GERD management for the benefit of patients, surgeons, and payers.

Aplos Medical president and CEO Claude Tihon said: “We are delighted by this monumental achievement, performed by Buckley and his team.

“The simple Omega PF device is designed to mitigate common issues seen with current GERD treatments.

“We look forward to further progress being made toward our ultimate goal of benefitting millions of individuals suffering from acid reflux.”

The company is working to advance Omega PF to support healthcare professionals in performing and improving patient experience.